{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-24-000020","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.389239+00:00","generated_at":"2026-06-02T01:24:31.190225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Alto Neuroscience Q1 net loss $13.4M; cash $205.9M; pipeline on track for multiple readouts","bullets":["Net loss $13.4M vs $7.3M YoY; R&D expenses $10.0M, G&A $4.4M, both up on clinical study costs and public company expenses.","Cash and equivalents $205.9M as of March 31, 2024; expects to fund operations into 2027.","Initiated Phase 2 study of ALTO-203 in MDD with anhedonia; reported positive Phase 1 data for transdermal ALTO-101 with improved tolerability.","Phase 2b studies of ALTO-100 and ALTO-300 in MDD enrolling; topline data for ALTO-100 expected 2H 2024, ALTO-300 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-24-000020","json":"https://secwatch.observer/filing/0001999480-24-000020.json","markdown":"https://secwatch.observer/filing/0001999480-24-000020.md","text":"https://secwatch.observer/filing/0001999480-24-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000020/0001999480-24-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000020/alto-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:24:31.190225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"677c8f1b1dfbe64c15322def20355afeb4384cb4","claim":"Alto Neuroscience, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"Alto Neuroscience, Inc. (the \"Company\") reported financial results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000020/0001999480-24-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}